[go: up one dir, main page]

PH12017501184B1 - Pharmaceutical composition for treating diabetes - Google Patents

Pharmaceutical composition for treating diabetes

Info

Publication number
PH12017501184B1
PH12017501184B1 PH12017501184A PH12017501184A PH12017501184B1 PH 12017501184 B1 PH12017501184 B1 PH 12017501184B1 PH 12017501184 A PH12017501184 A PH 12017501184A PH 12017501184 A PH12017501184 A PH 12017501184A PH 12017501184 B1 PH12017501184 B1 PH 12017501184B1
Authority
PH
Philippines
Prior art keywords
pharmaceutical composition
treating diabetes
dpp
inhibitor
metformin
Prior art date
Application number
PH12017501184A
Other languages
English (en)
Other versions
PH12017501184A1 (en
Inventor
Eon-Pyo Hong
Dong-Wook Kim
Hye-Suk Hong
Jin-Keon Pai
Original Assignee
Handok Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53500898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017501184(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Handok Inc filed Critical Handok Inc
Publication of PH12017501184A1 publication Critical patent/PH12017501184A1/en
Publication of PH12017501184B1 publication Critical patent/PH12017501184B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH12017501184A 2014-12-23 2017-06-22 Pharmaceutical composition for treating diabetes PH12017501184B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140186677A KR101526825B1 (ko) 2014-12-23 2014-12-23 당뇨병 치료용 약제학적 조성물
PCT/KR2015/014096 WO2016105084A2 (fr) 2014-12-23 2015-12-22 Composition pharmaceutique pour le traitement du diabète

Publications (2)

Publication Number Publication Date
PH12017501184A1 PH12017501184A1 (en) 2017-12-18
PH12017501184B1 true PH12017501184B1 (en) 2021-11-05

Family

ID=53500898

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501184A PH12017501184B1 (en) 2014-12-23 2017-06-22 Pharmaceutical composition for treating diabetes

Country Status (7)

Country Link
KR (1) KR101526825B1 (fr)
CN (1) CN107205969B (fr)
MY (1) MY196438A (fr)
PH (1) PH12017501184B1 (fr)
SG (1) SG11201705194XA (fr)
TW (1) TW201628602A (fr)
WO (1) WO2016105084A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106421794A (zh) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 一种用于治疗ⅱ型糖尿病的药物组合物及其制备方法
WO2019066359A2 (fr) * 2017-09-29 2019-04-04 한미약품 주식회사 Formulation pharmaceutique combinée comprenant de la dapagliflozine-l-proline et de la metformine
KR102500835B1 (ko) * 2017-10-24 2023-02-17 한미약품 주식회사 리나글립틴 및 메트포르민을 포함하는 복합제제 및 그의 제조방법
TR201721824A2 (tr) * 2017-12-26 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Li̇nagli̇pti̇n ve metformi̇n i̇çeren modi̇fi̇ye salim sağlayan kombi̇nasyon
CN113116842A (zh) * 2019-12-31 2021-07-16 广州玻思韬控释药业有限公司 胃滞留片
KR20230051096A (ko) * 2021-10-08 2023-04-17 (주)셀트리온 안정성이 개선된 당뇨병 치료용 약학 조성물
CN115715768B (zh) * 2022-11-24 2024-07-05 浙江昂利泰制药有限公司 一种小型西格列汀-二甲双胍缓释片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100705210B1 (ko) * 2004-09-23 2007-04-06 주식회사 한독약품 경구투여를 위한 당뇨병 치료용 약제학적 복합제제
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
DK1894567T3 (da) * 2005-06-03 2012-11-19 Mitsubishi Tanabe Pharma Corp Ledsagende farmaceutiske midler og anvendelse deraf
US8414921B2 (en) * 2005-12-16 2013-04-09 Merck Sharp & Dohme Corp. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
CN101168059A (zh) * 2007-10-12 2008-04-30 重庆医药工业研究院有限责任公司 一种含有双胍、磺酰脲和噻唑烷二酮的稳定的药物组合物及其制备方法
CN101168060B (zh) * 2007-10-12 2012-06-13 重庆医药工业研究院有限责任公司 一种含双胍和磺酰脲的稳定的药物组合物及其制备方法
CA2713361A1 (fr) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Compositions pharmaceutiques d'une association de metformine et d'un inhibiteur de la dipeptidyle peptidase-iv
MX2011008416A (es) * 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
JP6042330B2 (ja) * 2010-07-09 2016-12-14 ビーエイチヴィ ファーマ、インコーポレイテッド レモグリフロジンを含めた半減期が短い医薬品のための組合せ即時／遅延放出送達システム
UY33937A (es) * 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR101409330B1 (ko) * 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
KR20140013436A (ko) * 2012-07-24 2014-02-05 한미약품 주식회사 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
CN103285398B (zh) * 2013-06-28 2015-07-22 青岛黄海制药有限责任公司 含有dpp-ⅳ抑制剂和第二种糖尿病药物的复方制剂及其制备方法

Also Published As

Publication number Publication date
WO2016105084A3 (fr) 2016-09-09
CN107205969B (zh) 2020-06-30
PH12017501184A1 (en) 2017-12-18
CN107205969A (zh) 2017-09-26
WO2016105084A2 (fr) 2016-06-30
KR101526825B1 (ko) 2015-06-08
SG11201705194XA (en) 2017-07-28
MY196438A (en) 2023-04-11
TW201628602A (zh) 2016-08-16

Similar Documents

Publication Publication Date Title
PH12017501184B1 (en) Pharmaceutical composition for treating diabetes
AU2015208932A8 (en) (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase I inhibitors
EA033325B1 (ru) Ингибиторы бромодомена
ZA201708692B (en) Antibacterial compounds
MX2018012016A (es) Compuestos biciclicos.
PH12015502075B1 (en) Treatment of cataplexy
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
MX2018002962A (es) Compuestos para el tratamiento de enfermedades relacionadas con la produccion de especies de oxigeno reactivo (eor) mitocondrial.
IN2015DN03795A (fr)
MX370412B (es) Compuesto antimicotico.
TN2016000535A1 (en) Ppar compounds for use in the treatment of fibrotic diseases.
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
PH12017500613A1 (en) Improved peptide inhibitors of sodium channels
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
PH12017501897A1 (en) 2-thiopyrimidinones
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
MX369174B (es) Proceso para la preparación de un compuesto.
BR112015020973A2 (pt) fundo de panela e panela
MX2017006548A (es) Acido 2-octilciclopropil-1-carboxilico y sus isomeros y usos.
MX2016009494A (es) Derivados fenolicos sulfurados.
UA114811C2 (uk) Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
BR112015031978A2 (pt) fundo de panela e panela
MY189542A (en) A process for preparing compositions for an amalgam